OFS
VIRX

OneAscent Financial Services’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

OneAscent Financial Services’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-438
Closed -$11K – 205
2019
Q2 		$11K Buy
+438
New +$16.9K 0.01% 224

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OneAscent Financial Services's VIRX Position: Q3 2019 in Review

OneAscent Financial Services sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2019, closing a stake of 438 shares — an estimated $11K sold.

OneAscent Financial Services first reported a position in VIRX in Q2 2019 and held it in 1 quarter. The position peaked at $11K in Q2 2019. 49 funds tracked by Wall St. Rank hold VIRX as of Q3 2019.

  • OneAscent Financial Services reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • OneAscent Financial Services sold 438 Viracta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $11K.
  • OneAscent Financial Services first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • OneAscent Financial Services's Viracta Therapeutics, Inc. Common Stock position peaked at $11K in Q2 2019.
  • 49 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on OneAscent Financial Services's 13F filing for Q3 2019, filed 15 Nov 2019.